AEON Biopharma, Inc.

What they do

AEON holds exclusive development and commercialization rights to ABP-450 for therapeutic indications in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. ABP-450 is manufactured by Daewoong Pharmaceutical Co., Ltd. in a cGMP facility that has produced products approved by the FDA, Health Canada, and the European Commission. The same botulinum toxin complex is approved in the U.S. for aesthetic use as Jeuveau, marketed by Evolus, and is approved as a biosimilar in Mexico, India, and the Philippines. AEON's development program is focused exclusively on therapeutic indications.

Revenue drivers

• ABP-450 therapeutic botulinum toxin — Pre-revenue; the company has not obtained regulatory approvals for ABP-450 or generated product sales revenue from it.
• U.S. therapeutic botulinum toxin market — Target market estimated at approximately $3.3 billion in 2025 and $3.5 billion in 2026, projected to grow about 8% annually, historically dominated by a single branded product.
• Aesthetic botulinum toxin (reference product only) — The same toxin complex is marketed as Jeuveau in the U.S. for glabellar lines by Evolus, but AEON's rights cover therapeutic uses only, not the aesthetic sales.

Recent performance

AEON reported cash and cash equivalents of $3.4 million as of June 30, 2026, total assets of $5.9 million, total liabilities of $21.3 million, and shareholder equity of negative $15.4 million. In July 2026, the company completed an underwritten public offering with net upfront proceeds of approximately $13.6 million and up to an additional $34.0 million in potential gross proceeds from milestone warrants. Annual net income was $42.0 million in 2024 and negative $39.2 million in 2025; operating cash flow was negative $20.3 million in 2024 and negative $17.3 million in 2025. Diluted EPS was $72.93 in 2024 and negative $3.95 in 2025.

Strategy

AEON is pursuing regulatory approval in the U.S. through a Section 351(k) biosimilar BLA for ABP-450, targeting full-label market entry across all approved therapeutic indications. The company held a BPD Type 2a meeting with the FDA in January 2026 covering its analytical similarity strategy, and plans to complete the majority of its analytical comparability program in 2026 and request a BPD Type 2b meeting in 2026. Analytical studies reported a 100% amino acid sequence match between ABP-450 and Botox with 93% to 99% sequence coverage across the five proteins of the 900 kDa complex, plus similar potency and functional cleavage of SNAP-25. Management believes the biosimilar pathway may enable efficient development and broad label access and intends to minimize switching friction for prescribers and payers through label, dosing, dilution, and workflow alignment.

Risks

• Going concern and negative equity — Shareholder equity was negative $15.4 million at June 30, 2026, with total liabilities of $21.3 million against total assets of $5.9 million.
• No product revenue and history of losses — AEON has not obtained regulatory approvals for ABP-450 or generated product sales revenue from it, and it reported net losses of $39.2 million in 2025.
• Financing dependent on milestone warrants — The July 2026 financing provides runway only into the first quarter of 2027, and up to $34.0 million of additional gross proceeds depends on cash exercise of milestone warrants.
• Regulatory and scientific uncertainty — The FDA acknowledged scientific challenges in characterizing the 900 kDa botulinum neurotoxin complex, and the clinical pharmacology and comparative clinical study requirements remain undetermined pending a planned BPD Type 2b meeting.

Outlook

Management's primary focus for the second half of 2026 is obtaining FDA feedback on the next phase of development, including clinical pharmacology and comparative clinical study requirements for ABP-450. The company plans to complete the majority of its analytical comparability program in 2026 and request a BPD Type 2b meeting. Upfront proceeds from the July 2026 offering are expected to fund operations into the first quarter of 2027.